About DEXLEVO
DEXLEVO is a company based in Seoul (South Korea) founded in 2012. DEXLEVO has raised $21.87 million across 2 funding rounds from investors including Shinhan Financial Group, Smile Gate Investment and Hyundai Venture Investment. DEXLEVO operates in a competitive market with competitors including Incyte, LEO Pharma, Formation Bio, Arcutis and DermBiont, among others.
- Headquarter Seoul, South Korea
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Dexlevo Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$21.87 M (USD)
in 2 rounds
-
Latest Funding Round
$21.87 M (USD), Series B
Nov 25, 2021
-
Investors
Shinhan Financial Group
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of DEXLEVO
DEXLEVO has successfully raised a total of $21.87M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $21.87 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in DEXLEVO
DEXLEVO has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Shinhan Financial Group, Smile Gate Investment and Hyundai Venture Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investment firm focused on buyouts
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Financial group
|
Locked | Locked | Locked |
Investor details for DEXLEVO
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DEXLEVO
Investment portfolio details for DEXLEVO
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DEXLEVO
Detailed financials for DEXLEVO
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dexlevo Comparisons
Peer comparison for DEXLEVO
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DEXLEVO
DEXLEVO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Incyte, LEO Pharma, Formation Bio, Arcutis and DermBiont, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating dermatology diseases
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
Immunotherapeutic solutions for dermatological conditions are developed.
|
|
| Locked | Locked | Locked |
Microbial therapeutics for skin diseases are developed.
|
|
| Locked | Locked | Locked |
Pharmaceutical formulations for dermatology, gastroenterology, and wellness are manufactured.
|
Detailed competitors of DEXLEVO
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dexlevo
Complete news archive for DEXLEVO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DEXLEVO
DEXLEVO was founded in 2012 and raised its 1st funding round 6 years after it was founded.
DEXLEVO is headquartered in Seoul, South Korea.
DEXLEVO is a funded company, having raised a total of $21.87M across 2 funding rounds to date.
DEXLEVO was founded in 2012 and is based in Seoul, South Korea. Operations focus on the biotechnology sector, where biopolymer-based therapeutics for skin conditions are developed. Key products include Iniblanc, a collagen stimulator used for natural skin collagen regeneration in anti-aging treatments, and DXP01, a volumizing filler. Research and development activities are centered on advancing these dermal applications.
DEXLEVO's top competitors include LEO Pharma, Formation Bio and Arcutis.
DEXLEVO has 4 investors. Key investors include Shinhan Financial Group, Smile Gate Investment, Hyundai Venture Investment, and MAGNA Investment.